Centurium Capital Releases Carbon Neutral Strategy and Roadmap

April 22, 2022, Beijing – Centurium Capital (“Centurium), a leading private equity investment firm in China, today announced its carbon neutral goals and roadmap, underscoring the firm’s commitment to achieve carbon net zero at the firm level by 2025 and at the portfolio level by 2050. In addition, the firm also committed to reducing its employee’s per capita carbon emission by 25% by 2030.

Climate change is a common challenge faced by mankind today and its impact has become more visible in the past century. According to The Special Report on Global Warming of 1.5ºC by IPCC (Intergovernmental Panel on Climate Change), limiting global warming to 1.5ºC would require rapid, far-reaching, and unprecedented changes in all aspects of society. In response, the Chinese government has committed to reach carbon peak by 2030 and achieve net zero by 2060.

Centurium’s carbon neutral goals are a testament to its support for sustainable growth. In the past few months, Centurium has worked with a carbon neutral specialist consulting firm to complete its carbon emission assessment for 2021. The firm will continue to track its carbon footprint annually.

At the portfolio company level, the firm will strengthen its training efforts to support its portfolio companies in areas of carbon management. Meanwhile, Centurium plans to systematically assess its portfolio companies’ positive and negative contributions for sustainable economic growth and encourage them to disclose carbon management performance regularly.

With the implementation of more robust carbon management efforts in the coming years, Centurium plans to include carbon net zero as part of its corporate development strategy. Meanwhile, climate change risk assessment will be included in the firm’s investment strategy and risk management framework.

By 2050, Centurium commits to reach carbon net zero at its portfolio level. The firm will also include carbon management in its selection criteria of suppliers and enhance its green purchase program.

About Centurium Capital

Centurium is a leading private equity investment firm in China focused on investing in consumer, healthcare, and business services sectors. With a hands-on, operation centric “Invest to Transform” model, Centurium provides bespoke solutions to companies to unlock growth potential and promotes business transformation through technology and business innovation.

Arion Cancer Hospital

Arion is a private tertiary cancer hospital in Beijing, jointly founded and invested by Amcare Group, Centurium Capital and other financial/strategic investors. Dedicated to personalized full-cycle cancer treatments and management, from prevention and early test of symptoms, to adoption of most advanced cancer treatment methods, the hospital brings globally-leading treatment skills, concept and talents to cancer patients in China.

Located in Daxing District in South Beijing, Arion Cancer Hospital covers an area of over 24,000 square meters with 400 beds for inpatients, including 60 day-time beds for chemotherapy and 24 ICU/emergency beds.

Genebox

Genebox is the leading direct-to-consumer genetic testing platform in China, committed to provide accurate, useful and convenient genetic testing product and services to hundreds of millions Chinese consumers.

Since its founding, “Customer Centric” has been Genebox’s core principle and the company is investing heavily on consumer experience, including: building its own lab and software to ensure the fast and accurate delivery of DNA testing results; relentlessly expanding its competitive advantage by offering better product and technology; adopting an innovative, customer-oriented and low-cost marketing model.

Genebox’s mission is to help Chinese consumers access to and understand their genetic information, and live happier and healthier.

In the future, Genebox will continue to develop its consumer ecosystem, providing more content and applications based on users’ personal genetic data. In addition, Genebox will invest reasonable resources on DNA testing technology, to strengthen its long-term competitive advantage.

Centurium Capital Becomes Signatory of United Nations-supported Principles For Responsible Investment

Beijing, February 11, 2022 – Centurium Capital, a leading private equity investment firm in China, today announced that it has become a signatory of the United Nations-supported Principles for Responsible Investment (PRI), demonstrating the firm’s continuous commitment to environmental, social and governance (ESG) issues and initiatives.

Launched in 2006 by the former UN Secretary-General, Kofi Annan, the PRI has become the world’s leading proponent of responsible investment. It works to support an international network of investor signatories in understanding the implications of ESG factors and integrating these factors into their investment practices and ownership policies.

Luo Nan, head of the PRI China, extended a warm welcome to Centurium Capital. “In signing up to PRI, Centurium Capital shows commitment to practicing responsible investment. It is an important step in its continued ESG practice. The development of responsible investment is now growing rapidly and we look forward to more investors joining the journey,” she said.

David Li, Chairman and CEO of Centurium Capital, commented, “We are excited to join the leading international network to help promote the awareness and adoption of ESG best practices in China. ESG forms an integral part of our value-creation and ‘invest to transform’ investment approach, and we look forward to the partnership with the PRI to further enhance our ESG practices and bring positive impacts to our portfolio companies.”

Centurium Capital was founded in 2017 with the investment thesis of “invest to transform”. It has grown to be a leading private equity investment firm in China and manages both RMB and US dollar funds. Centurium Capital primarily focuses on China’s consumer, business services and healthcare sectors.

In addition to integrating ESG factors into the whole investment process, Centurium Capital has established its ESG committee consisting of IC members and directors from various departments of the firm. The committee’s goal is to drive a holistic ESG strategy and governance framework and oversee ESG initiatives undertaken at Centurium and companies within its portfolio.

Centurium Capital offers ESG supports to its portfolio companies, such as providing ESG training and ESG management support, sharing of knowledge and best practices, and encouraging appropriate disclosure of ESG issues.

Consortium Led by Centurium Capital Acquires Stake in Luckin Coffee Through Secondary Purchase

January 27, 2022, Beijing – Centurium Capital, a leading private equity investment firm in China, announced today that it has led a consortium to complete a transaction to purchase an aggregate of 383,425,748 Class A ordinary shares of Luckin Coffee (the “Company”) from certain sellers (the “Secondary Sale”). Other consortium members include IDG Capital and Ares SSG Capital Management.

The sellers are affiliates of and were formerly controlled by certain former management members of the Company and their families, and were ordered to be wound up and are currently in liquidation pursuant to an order of the Grand Court of the Cayman Islands and pursuant to orders of the Eastern Caribbean Supreme Court in the High Court of Justice of the British Virgin Islands (the “BVI Court”). The joint liquidators appointed in respect of the sellers have exercised their statutory powers to enter into definitive documents to give effect to the Secondary Sale. On January 17, 2022, the BVI Court sanctioned transactions that form part of the Secondary Sale, as required by the securities purchase agreement that gave effect to the Secondary Sale.

The Board of Directors and joint provisional liquidators of Luckin Coffee have determined the Secondary Sale to be in the long-term best interest of the Company, and accordingly approved the transaction.

Upon the closing of the Secondary Sale and after taking account of its previous investments, Centurium Capital has become the controlling shareholder of Luckin Coffee, holding more than 50% of the voting interest of the Company.

Statement from Centurium Capital:

We are committed to supporting our portfolio companies to build sustainable business models, robust and transparent corporate governance and responsible management systems, and we will continue to support Luckin’s long-term growth and development.

Centurium Capital is a leading private equity investment firm in China, with primary focuses on China’s consumer, business services and healthcare sectors.

GOUMEE

GOUMEE is a tech-driven online brand operation and marketing service provider in fashion industry. It focuses on live-streaming e-commerce operation and influencer marketing, helping brands to acquire customers in new traffic channels and developing new products. GOUMEE is a first-tier live-streaming e-commerce Douyin Partner and a top notch service provider in both T-mall and Douyin.

China Biologic Privatization Transaction Led by Centurium Capital Wins AVCJ “Deal of the Year – Large Cap”

November 16, 2021, Hong Kong – The Centurium Capital-led privatization of leading plasma-based biopharmaceutical company China Biologic Products Holdings Inc. (“China Biologic” or the “Company”) was awarded “Deal of the Year – Large Cap” by Asia Venture Capital Journal (AVCJ) at its annual award ceremony on November 15 in Hong Kong.

A buyer consortium led by Centurium Capital first announced its indicative proposal to privatize the Nasdaq-listed China Biologic (Nasdaq: CBPO) on September 18, 2019. On November 19, 2020, the two sides had reached an agreement for the consortium to purchase the outstanding shares not already owned by the consortium members at US$120 per share, implying a valuation of US$4.76 billion for the Company. The consortium members also included CITIC Capital, Hillhouse Capital, Temasek and the management team. The privatization transaction was closed on April 20, 2021.

Zhixing Chen, Managing Director of Centurium Capital, commented, “It was a long journey for us to close the China Biologic transaction, which is one of the largest privatization deals in China’s healthcare space in recent years. I want to take this opportunity to thank our investors, our team and friends who supported us along the way. Going forward, we will continue to work closely with the management team at China Biologic and bring the Company to the next level.”

Centurium Capital first invested in China Biologic in August 2018. Founded in 2002, China Biologic Products is a leading fully integrated plasma-based biopharmaceutical company in China. The Company’s products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosage forms of plasma products.

China Biologic is also engaged in the sale of medical devices, primarily regenerative medical biomaterial products. The Company sells its products to hospitals, distributors and other healthcare facilities in China.

AVCJ has been the leading source of information on private equity and venture capital activities in Asia since its establishment in 1987. AVCJ presents annual awards across categories recognizing excellence in fundraising, investment, exits, responsible investment, and value creation.

Centurium Capital is a leading private equity investment firm in China and primarily focuses on investing in China’s consumer, business services and healthcare sectors. As a transformational capital provider with a focus on business model innovation and resolving structural deficiencies to unlock growth potential, Centurium pursues a hands-on and operations-centric investment approach to drive value creation and generate long term shareholder value.

Centurium Capital Invests US$100 Million in Leading Chinese SaaS-based Group Catering Technology Company Meican

November 10, 2021, Beijing, China – Meican (the “Company”), a leading Chinese SaaS-based group catering technology company, announced today that it has completed E-round financing of US$100 million invested by Centurium Capital, a leading private equity investment management firm in China. The financing is expected to enhance Meican’s capabilities and investments in product research and development, global customer acquisition, supply chain diversification, and human resources development.

Founded in 2011, Meican is China’s largest group catering solutions provider. The Company offers comprehensive catering solutions to corporate clients and their employees, including both on-premise and off-premise catering and SaaS solutions. It also offers SaaS solutions to traditional group dining players, including digital ordering, integrated payment processing, catering operation, corporate fee control, as well as reporting & analytics.

The Company’s clients include Bytedance, Alibaba, SF Express, China CITIC Bank, Pacific Insurance, SASAC, Peking University People’s Hospital and China Southwest Aviation University, and numerous others. Through its SaaS technology and innovative solutions, Meican has transformed and modernized the traditional group catering industry.

Statistics show that the group catering market in China exceeded RMB1.5 trillion in 2020, serving 670 million customers while growing at over 15 percent annually. However, the Chinese group catering industry is still very fragmented, with a CR10 (market share of top 10 players) of less than five percent in China, which is in sharp contrast with a CR10 of 60 to 80 percent in developed markets such as the United States, Europe, Japan and South Korea. This demonstrates huge growth and consolidation potential.

Xiao Zhao, Co-founder and CEO of Meican, commented, “Thanks to increasing penetration of digitalization and demand for a better group catering experience, the industry is going through a profound transformation. We will continue to invest in the diversification and digitalization of our supply chain to further upgrade the overall industry infrastructure and solidify our market-leading position. With synergies from our core advantages in SaaS solutions and unique product offering, we are confident that Meican will accelerate its growth and expansion to further tap into the trillion-yuan group catering market.”

Gary Liu, Managing Director of Centurium Capital, commented, “Serving two huge markets of business services and catering, Meican has built a very unique business model and developed innovative solutions through years of hard work. We believe there is still a huge unmet demand from corporate clients and their employees for modern, standardized and diversified group catering services. Meican has grown significantly over the past several years, connected a large number of traditional catering service providers, and accumulated deep industry expertise. We are pleased to partner with Meican to support the Company’s expansion and help them to continue to upgrade their product and service offerings.”

Today, Meican’s products and services cover nearly 100 cities across China, including Beijing, Shanghai, Guangzhou, Shenzhen, Chengdu, Nanjing, Hangzhou, Suzhou, Wuhan, and serve thousands of corporate customers and merchant partners.


Centurium Capital is a leading private equity investment firm in China and primarily focuses on investing in China’s consumer, business services and healthcare sectors. As a transformational capital provider with a focus on business model innovation and resolving structural deficiencies to unlock growth potential, Centurium pursues a hands-on and operations-centric investment approach to drive value creation and generate long term shareholder value.

Innogen

Shanghai Innogen Pharmaceutical Technology Co., Ltd.  is a science-driven biotechnology company dedicated to the research and development of innovative and affordable medicines for diabetes and other metabolic disease patients. Innogen’s pipeline in metabolic disease, including Type 1 & 2 diabetes, obesity and NASH, is independently developed and has global market rights.

Supaglutide, Innogen’s leading drug candidate, is a long-acting humanized GLP-1 receptor agonist. Currently under phase III trials for T2D, Supaglutide will be the first humanized long-acting GLP-1 drug that originated from China. Continuously increasing diabetes patient population and sub-optimal glucose control provides an enormous potential market for Supaglutide both in China and across the globe. Other indications for Supaglutide such as obesity and NASH are also under development.

Chinese Online Training Platform Yunxuetang Closes $190 Million Series E at a $1 billion Valuation

March 30, 2021, Beijing – Yunxuetang (YXT), a China-based online corporate training services provider, has recently completed two series E rounds, E1+E2, within three months of each other, totaling $190 million. Venture capital firm Matrix Partners China led the series E2 tranche with additional contributions from Sequoia Capital China and Hundreds Capital.

The E1 round was closed in January 2021 and led by Tencent. Prior to this round, Yunxuetang received multiple rounds of financing from top-tier private equity managers such as Centurium Capital, YF Capital, SIG, Ximalaya, and Everest VC. After the completion the series E financing, Yunxuetang become a unicorn and best-funded corporate training service provider in the industry.

This round of financing will be used for AI technology and software product innovation, data center and IT center construction, content development and customer experience enhancement.

Corporate training has grown year over year, but it gained stronger growth momentum in 2020 due the COVID-19 outbreak. The pandemic resulted in an urgent need for digital transformation, and companies quickly shifted from offline training to online. As the largest and most comprehensive corporate training technology company in China, Yunxuetang has led the way in providing business digitalization solutions.

Yunxuetang, founded in 2011, offers end-to-end corporate training solutions including training infrastructure establishment, training materials development, training program maintenance, data analysis and vendor management to meet the increasing demands for more efficient staff training as Chinese companies grow and evolve.